key: cord-0751859-rfpg4cng authors: Yıldırım, Özge Turgay; Kaya, Şeyhmus title: The Atherogenic Index of Plasma as a Predictor of Mortality in Patients with COVID-19 date: 2021-01-26 journal: Heart Lung DOI: 10.1016/j.hrtlng.2021.01.016 sha: 0fa4e2e2f835fb07727ea9dee4da62fb1977f7e8 doc_id: 751859 cord_uid: rfpg4cng BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a global health threat, and thus, an early and effective set of predictors is needed to manage the course of the disease. OBJECTIVES: We aim to determine the effect of SARS-CoV-2 on lipid profile and to evaluate whether the atherogenic index of plasma (AIP) could be used to predict in-hospital mortality in COVID-19 patients. METHODS: In this retrospective chart review study, a total of 139 confirmed COVID-19 patients, whose diagnoses are confirmed by PCR and computerized tomography results, are enrolled. The study population is divided into two groups: the deceased patient group and the survivor group. For each patient, fasting total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and the triglyceride values are obtained from the laboratory tests required at the admission to hospital. Finally, the AIP is calculated as the base 10 logarithm of the triglyceride to HDL-C ratio. Distributional normality of the data is checked and depending on the normality of the data, either T test or Mann Whithey U test is employed to compare the two aforementioned study groups. RESULTS: Mean age of the study population is 49.2±20.8 and 61.2% (n=85) is male. Out of the 139 patients 26 have deceased and the remaining 113 patients survived the disease. Mean age of the deceased patients was 71.8±8.9 and mean age of the survivor patients is 44.0±19.2 (p<0.001). The deceased group had more patients with hypertension (50.0% vs. 23.0, p=0.006), diabetes mellitus (35.6% vs. 10.6%, p=0.002), cardiovascular diseases (23.1% vs. 4.4%, p=0.001), chronic renal insufficiency (11.5% vs. 0.9%, p=0.003) and atrial fibrillation (7.7% vs 0%, p=0.003). The AIP values in the deceased group are found to be statistically higher (p<0.001) than the survivor group. As a measure of mortality, the area under the operating characteristic curve for the AIP is calculated as 0.850 (95% confidence interval: 0.772-0.928) along with the optimal cut-off value of 0.6285 (78.6% sensitivity and 80.5% specificity). Furthermore, the AIP value is observed to be elevated in patients with pneumonia, intubation history, and intensive care admission during hospital stay (p=0.002, p<0.001 and p<0.001, respectively). Finally, compared to the survivor group, total cholesterol, HDL-C, LDL-C values are lower (p=0.004, p<0.001 and p<0.001, respectively) and triglyceride levels are higher (p<0.001) in deceased patients. CONCLUSION: In this study, we show that the AIP levels higher than 0.6285 can predict in-hospital mortality for COVID-19 patients. Moreover, the AIP emerges as a good candidate to be used as an early biomarker to predict pneumonia, intubation and intensive care need. Hence, regular check of the AIP levels in COVID-19 patients can improve management of these patients and prevent deterioration of the disease. After its emergence in Wuhan City, Hubei Province, China, SARS-CoV-2 has gained entry to many countries across the globe, causing a global pandemic [1] [2] [3] . As a consequence, many scientists investigated the disease with intense efforts. Numerous studies have been published, that investigate the mechanism of the virus, its' spread, symptoms, its' effects on the body, and the possible treatment methods [4] [5] [6] [7] [8] [9] . One of the prominent results in these studies is that some hematological and biochemical markers can predict the prognosis of the disease 10 . As an extension of this finding, availability of indicators to predict the prognosis of the disease and whether it will end in mortality for the patient at the beginning of the disease, would make it possible to identify the risky patients and indicate which patients do not need a close follow-up. Such an indicator stems from the lipids, which are the basic building blocks of the cell and the virus membranes 11 . Viral infections can cause changes in the lipid profile of the host organism. This occurs because the virus controls the host metabolism in order to meet the requirements for its replication 12 . Previously published studies, especially on RNA viruses, indicated the effects of these viruses on lipid metabolism. It has been shown that LDL-C level decreases and HDL-C level increases in HIV-infected patients 13 . In addition, it was found that the triglyceride level increased in the advanced stages of the disease 14 . Triglyceride and HDL-C, which measure cardiovascular mortality risk, are two lipids that is examined routinely. Furthermore, the logarithmic transformation of triglyceride to HDL-C ratio is known as the Atherogenic Index of Plasma (AIP) 15 . The AIP is associated with chronic diseases such as diabetes, hypertension and cardiovascular disease [16] [17] [18] [19] [20] . Additionally, the relationship between the severity of viral infections and the AIP has been identified 21 . Moreover, there are studies which discuss the impact of SARS-CoV on the disorders of patients' lipid profile in long-term, while their short term effects are not clear 22 . In this study, our aim is to investigate the effect of SARS-CoV-2 on lipid profile and the effect of the AIP on survival in COVID-19. For this study, 561 patients who were admitted to our center and were diagnosed with laboratory or computerized tomography confirmed COVID-19 are evaluated. This study is designed to be retrospective; as a consequence, 419 out of the original 561 patients who did not have their lipid profile evaluated at their hospitalization had to be excluded. 3 patients out of the remaining 142 patients were under statin and/or fenofibrate treatment, thus, also excluded from the study. The remaining 139 patients are enrolled in this study. The data set is from the confirmed COVID-19 patients who had been hospitalized at our health center from 20.03.2020 to 26.05.2020. It is collected and evaluated by two physicians and independently reviewed by the researchers to double-check collected data. Demographic and clinical data, as well as previous medication histories are collected from hospital medical records. Fasting total cholesterol, HDL-C, LDL-C, and triglyceride values are obtained from the results of laboratory tests at the time of admission to the hospital. Finally, the AIP is calculated as the base 10 logarithm of the triglyceride to HDL-C ratio. Only the laboratory values measured on the first day of hospitalization and before treatment were used in the study. The values checked in the following days were definitely not used for the study. Patients without a lipid profile assessment in their blood parameters on the first day were excluded from the study. The data is summarized in the form of "mean ± standard deviation" or "median (interquartile (Table 2) . ROC curve is constructed to evaluate predictive value of in-hospital mortality of the AIP in patients with COVID-19 ( Figure 1 ). The area under the curve of the AIP is 0.850 (95% confidence interval (CI): 0.772-0.928). The optimal cut-off value is calculated as 0.6285 with a sensitivity of 78.6% and specificity of 80.5%. The AIP value is statistically higher in confirmed pneumonia patients compared to patients without pneumonia (p=0.002). Patients who were intubated during hospitalization have higher AIP values (p < 0.001). Patients who were followed in intensive care unit also have higher AIP values than patients followed in normal hospital room (p < 0.001). Logistic regression analysis was performed with the AIP, gender, age and comorbidities of the patients to evaluate the explanatory power of the variables on mortality. Regression analysis showed that age and the AIP are independently associated with mortality (Table 4) . Since there was a significant difference between age and underlying diseases in the deceased and survivor groups, a new analysis was performed by excluding random patients from both study groups. In this analysis, the deceased and survivor groups consisted of 21 patients each, and these two groups did not differ in terms of age, gender and underlying disease status (Table 5 ). This statistical analysis showed similar results with the analysis of the whole study population. p=0.005) levels were lower in deceased group compared to the survivor group (Table 6 ). Our study states that patients that are deceased due to COVID- 19 12 showed that viruses can modulate the lipid metabolism of the host cell for its optimal viral replication. The data for SARS-CoV-2 and its effect on the lipid metabolism is limited since its emergence is relatively recent. In our study total cholesterol, HDL-C and LDL-C was lower at the patients who are deceased. We may speculate that the viral In this study we have not compared the COVID-19 patients with non-infected population, but rather we compared patients who have survived the disease with patients who have deceased. The deceased patients had higher triglyceride levels which shows patients with worse prognosis has higher triglyceride levels. Even though the previously mentioned studies are on other RNA viruses, results seem similar, hence an identical mechanism may play a role on lipid metabolism of the host. High triglyceride and low HDL-C levels are both risk factors for cardiovascular diseases 35 . The AIP combines these two risk factors and several studies performed on this subject and showed that the AIP is associated with atherosclerosis, cardiovascular diseases, diabetes mellitus, hypertension, vascular and endothelial damage [16] [17] [18] [19] [20] . SARS-CoV-2 affects cardiovascular system on different levels. The patients may have myocardial injury, myocarditis, heart failure and it may cause acute myocardial infarction due to increased hypercoagulability and inflammation 26-38 . In our study, the deceased patient group had higher AIP levels when compared to the survivor group. This finding suggests that higher AIP is related to worse prognosis in COVID-19 patients. 45 show that viral load is higher in patients who died compared to patients whom recovered during COVID-19 pandemic. There are also studies that show the correlation between viral load and biochemical and hematological markers. For example, higher LDH, troponin I and lower lymphocyte levels are associated with viral load [45] [46] [47] [48] . Likewise, the patients in the deceased group, patients with pneumonia, intubation history and intensive care need have higher AIP values in our study. These results show that patients with worse outcomes have higher AIP. Based on these results, we suggest that elevated AIP may be associated with increased viral load and an indicator for worse prognosis in COVID-19 patients. We found out that an AIP level of 0.6285 can be used as a cut-off value for mortality with a sensitivity of 78.6% and specificity of 80.5%. As far as we know this is the first study to evaluate the relationship between the AIP and mortality in COVID-19 patients. The AIP values are also higher in patients with pneumonia, intubated patients and patients in intensive care unit. This results show that along with mortality, higher AIP values also predicts pneumonia incidence, intensive care unit and intubation need in COVID-19 patients. Several chronic disorders like cardiovascular diseases, hypertension, diabetes mellitus, atrial fibrillation and chronic renal insufficiency are associated with worse outcomes in COVID-19 patients 28,49-51 . In our study, patients in the deceased group have higher rates of cardiovascular diseases, hypertension, diabetes mellitus, chronic renal insufficiency and atrial fibrillation history than survivor group. As already discussed, previous studies support these findings as well. Finally, patients with pre-existing morbidities should be evaluated more carefully to prevent worse outcomes and mortality in these patients. Major limitation of our study is the small sample size. A multicenter study with a larger sample size should be performed to strengthen and improve upon the findings in this study. Additionally, majority of the confirmed cases did not have lipid profile values due to the retrospective design of the study. The exclusion of these patients at the beginning further reduces the size of the patients enrolled in the study. Furthermore, our study only includes hospitalized patients. It would be superior to perform the study on every confirmed COVID-19 case. COVID-19 quickly became a global pandemic and still continues to cause death among people especially with previous comorbidities 1-3,28,49-51 . Several hematological and biochemical parameters have been shown to be related to mortality among COVID-19 patients [45] [46] [47] [48] . Our study showed that the AIP may be used as a biomarker for mortality. The AIP on admission greater than 0.6285 value can be an indicator of in-hospital mortality in patients with COVID-19. Patients with higher AIP values should be treated carefully and followed up for clinically worse outcomes. In addition, higher triglyceride level and lower total cholesterol, LDL-C and HDL-C values are observed in COVID-patients who were deceased in the process which may be an effect of the SARS-CoV-2 on lipid metabolism of the host subject. No funding was taken for this study. The authors declare that they have no conflict of interest. Data are presented as n, mean±standart deviation or n (%) unless otherwise stated. A Novel Coronavirus from Patients with Pneumonia in China Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study The use of Angiotensin converting enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARB) in COVID-19 Pandemic SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells Cardiovascular disease and COVID-19 COVID-19 and Multiorgan Response Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19 Role of lipids in virus replication Lipidomic Profiling Reveals Significant Perturbations of Intracellular Lipid Homeostasis in Enterovirus-Infected Cells Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case-control study Plasma lipids in HIV-infected patients: a prospective study in 95 patients The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoproteindepleted plasma (FER(HDL)) Atherogenic index of plasma triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography Atherogenic Index of Plasma Hüseyı̇noğlu Aydın A . Evaluation of atherogenic index of plasma levels at hypertensive patients Lipids profile among ART-naïve HIV infected patients and men who have sex with men in China: a case control study Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Severe acute respiratory syndrome Middle East Respiratory Syndrome Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome Initial viral load and the outcomes of SARS Chronological Changes of Viral Shedding in Adult Inpatients with COVID-19 in Wuhan, China Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19 Viral loads in throat and anal swabs in children infected with SARS-CoV-2 Saliva is a reliable tool to detect SARS-CoV-2 COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort The Dilemma of Renal Involvement in COVID-19: A Systematic Review